Results 81 to 90 of about 44,865 (239)

In-depth characterization of miRNome in papillary thyroid cancer with BRAF V600E mutation

Progress in Microbes and Molecular Biology, 2020
MicroRNAs (miRNAs) are small non-coding RNAs, which play a critical regulatory role in papillary thyroid carcinoma (PTC). BRAF V600E is a hotspot mutation occurring in a majority of PTC cases and is proposed to be associated with poor clinical outcomes.
Azliana Mohamad Yusof, Francis Yew Fu Tieng, Rohaizak Muhammad, Shahrun Niza Abdullah Suhaimi, Isa Mohamed Rose, Sazuita Saidin, Rahman Jamal, Imilia Ismail, Nurul-Syakima Ab Mutalib   +8 more
doaj   +1 more source

Molecular Diagnostics in Thyroid Nodules: Current Applications, Clinical Value, and Future Perspective

Med Research, EarlyView.
ABSTRACT Molecular diagnostics have become an important adjunct to ultrasonography and fine‐needle aspiration (FNA) for thyroid nodules, especially in Bethesda III/IV cytology where malignancy risk is uncertain. This narrative review summarizes the diagnostic and prognostic value of key genomic drivers (BRAF V600E, RAS, RET, TERT, and selected fusions)
Guohui Xiao, Min Ding, Zhixue Min, Yihan Dong, Xuanye Cao, Qiang Lu, Cong Chen, Yahui Wu, Xin Guo, Zhen Wu, Jing Xie, Dan Xu, Haizhen Chen, Rongli Xie, Jian Fei   +14 more
wiley   +1 more source

Frequent mutation of K-RAS in addition to BRAF V600E in Ameloblastoma – An immunohistochemical study

Oral Oncology Reports
Background: Ameloblastoma is the most frequently encountered, enigmatic odontogenic tumor whose etiopathogenesis is still controversial. Understanding the pathogenic mechanism involved in Ameloblastoma and its proliferation aids in determining the best ...
Aishwariya Mohanty, Abikshyeet Panda, Pallavi Mishra, Lipsa Bhuyan, Harish Kumar   +4 more
doaj   +1 more source

Clinical Characteristics and Treatment Outcomes of 65 Patients With BRAF-Mutated Non-small Cell Lung Cancer

Frontiers in Oncology, 2020
BRAF mutation is an oncogenic driver gene in non-small cell lung cancer (NSCLC) with low frequency. The data of patients with NSCLC harboring BRAF mutations is rare.
Yuxin Mu, Ke Yang, Xuezhi Hao, Yan Wang, Lin Wang, Yutao Liu, Lin Lin, Junling Li, Puyuan Xing   +8 more
doaj   +1 more source

BRAFV600E mutation positive metastatic melanoma in a young woman treated with anti-BRAF/anti MEK combination: a case report [PDF]

, 2015
The recent Combi-v [1] and Combi-d [2,3], phase III randomized trials, showed, respectively, an OS benefit with Dabrafenib/Trametinib combination versus Vemurafenib and an improvement in PFS and ORR with the same combination versus Dabrafenib alone ...
CORTESI, Enrico, GIOVANNONI, SARA, Giuliana, Caprio, MEZI, Silvia, MODICA, DANIELA, URBANO, FEDERICA, VERKHOVSKAIA, SOFIA   +6 more
core   +2 more sources

Fibrosis‐Driven Surgical Risk After Thyroid Nodule Ablation: Quantitative Clinicopathological Determinants of Complications in Post‐Ablative Thyroidectomy—A Retrospective Cohort Study

World Journal of Surgery, EarlyView.
Thermal ablation is increasingly used for selected benign and low‐risk thyroid nodules, yet some patients still require thyroidectomy for regrowth, persistent symptoms, or new oncologic concern. The surgical and pathological impact of ablation‐induced remodeling remains incompletely defined.
Daqi Zhang, Alvino Boero, Giacomo Gazzano, Andrea Satta, Laura Fugazzola, Carla Colombo, Francesco Brucchi, Gianlorenzo Dionigi   +7 more
wiley   +1 more source

Mutational Analysis in Pediatric Thyroid Cancer and Correlations with Age, Ethnicity, and Clinical Presentation. [PDF]

, 2016
BackgroundWell-differentiated thyroid cancer (WDTC) incidence in pediatrics is rising, most being papillary thyroid carcinoma (PTC). The objective of the study was to assess the prevalence of different mutations in pediatric WDTC and correlate the ...
Cheng, Shih-Min, Hantash, Feras M, Jiang, Wen, McPhaul, Michael J, Newbury, Robert O, Newfield, Ron S, Nikita, Maria Eleni, Phillips, Susan A, Reitz, Richard E, Waldman, Frederic M   +9 more
core   +1 more source

Določanje mutacije V600E v genu BRAF

Onkologija, 2010
The most common BRAF mutation, which accounts for more than 90% of all BRAF mutations described in different malignancies, is a glutamic acid for valin substitution at position 600 (V600E). BRAF gene carrying V600E mutation is termed BrafV600E oncogene.
Ličar, Alenka, Novaković, Srdjan, Škerl, Petra   +2 more
openaire   +3 more sources

Advances and Future Perspectives for the Management of Non‐Small Cell Lung Cancer in Australia: A Narrative Review

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Lung cancer remains Australia's leading cause of cancer death. With new screening and evolving therapies, equitable access and workforce readiness are essential. This review discusses current and emerging treatments for NSCLC in Australia, clinical trials underway, and future directions in delivering optimal, accessible care nationwide.
Lauren Julia Brown, Graham Meredith, Bo Gao, Pei Ding, Harriet Gee, Inês Pires da Silva, Adnan Nagrial, Eric Hau   +7 more
wiley   +1 more source

Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing.

PLoS ONE, 2013
BRAF inhibitors have demonstrated improvement of overall survival in patients with metastatic melanoma and BRAF(V600) mutations. In order to evaluate BRAF tumor heterogeneity between primary and metastatic site, we have evaluated the performance of ...
Lucile Boursault, Véronique Haddad, Béatrice Vergier, David Cappellen, Severine Verdon, Jean-Pierre Bellocq, Thomas Jouary, Jean-Philippe Merlio   +7 more
doaj   +1 more source